title: Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
abstract: Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype-guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics.
authors.affiliation: Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
authors.forename: L H
authors.initials: LH
authors.lastname: Cavallari
authors.affiliation: 1] Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA [2] Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, Illinois, USA [3] Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Nutescu
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D002986:Clinical Trials as Topic; D065729:Cytochrome P-450 CYP2C9; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics; D044469:Racial Groups; D064417:Vitamin K Epoxide Reductases / Q000235:genetics; D014859:Warfarin / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases